Dr. Roffler, Steve R. 's publons link picture

Dr. Roffler, Steve R.

Distinguished Research Fellow
Division Chief
  • 02-2652-3079 (Lab) (Room No: N233)
  • 02-2782-9142 (Fax)
Specialty:
  1. Antibody Engineering
  2. Directed Molecular Evolution
  3. Prodrugs
Education and Positions:

  • Ph.D. University of California, Berkeley

1. Antibody engineering: We are engineering and investigating bispecific antibodies to deliver nanomedicines into cancer cells for improved anticancer selectivity and efficacy.    

2. Nanomedicine: New approaches to stably load and retain hydrophobic drugs in liposomal nanocarriers are under development.    

3. Directed molecular evolution: We perform directed molecular evolution of human enzymes for antibody-directed enzyme prodrug therapy. 

 4. Prodrug therapy: Anticancer prodrugs that are selectively activated in the tumor microenvironment are under investigation to improve the selectivity and therapeutic efficacy of cancer treatment. 

5. Anti-PEG antibodies: We develop antibodies to assay PEGylated drugs in human serum and are extending these studies to investigating the impact of pre-existing and induced anti-PEG antibodies on the therapeutic efficacy and safety of PEGylated medicines.

Our Team
Team photo

Journal 176 Book 2

  1. Chen Bing-Mae, Chen Even, Lin Yi-Chen, Tran Trieu Thi My, Turjeman Keren, Yang Shih-Hung, Cheng Tian-Lu, Barenholz Yechezkel, Roffler Steve R. Liposomes with Low Levels of Grafted Poly(ethylene glycol) Remain Susceptible to Destabilization by Anti-Poly(ethylene glycol) Antibodies. ACS Nano epub ahead of print, NA-NA (2024-08) [JCR] [WOS]
  2. Tseng Yi-Han, Lin Hsuan-Pei, Lin Sung-Yao, Chen Bing-Mae, Vo Thanh Nguyet Nguyen, Yang Shih-Hung, Lin Yi-Chen, Prijovic Zeljko, Czosseck Andreas, Leu Yu-Lin, Roffler Steve R Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs. Journal of Controlled Release 369, 179-198 (2024-05) [JCR] [WOS]
  3. Tran Trieu TM, Roffler Steve R Interactions between nanoparticle corona proteins and the immune system. Current Opinion in Biotechnology 84, 103010 (2023-12) [JCR] [WOS]
  4. Chen Huei-Jen, Cheng Yi-An, Chen Yu-Tung, Li Chia-Ching, Huang Bo-Cheng, Hong Shih-Ting, Chen I.-Ju, Ho Kai-Wen, Chen Chiao-Yun, Chen Fang-Ming, Wang Jaw-Yuan, Roffler Steve R., Cheng Tian-Lu, Wu Dung-Ho Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20). Cancer Nanotechnology 14(1), 78 (2023-10) [JCR] [WOS]
  5. Beishenaliev Adilet, Loke Yean Leng, Goh Sook Jing, Geo Hui Nee, Mugila Malar, Misran Misni, Chung Lip Yong, Kiew Lik Voon, Roffler Steve, Teo Yin Yin Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review. Journal of Controlled Release 359, 268-286 (2023-07) [JCR] [WOS]
  6. Chen Wei-An, Chang Deng-Yuan, Chen Bing-Mae, Lin Yi-Chen, Barenholz Yechezekel, Roffler Steve R. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines. ACS Nano 17(6), 5757-5772 (2023-03) [JCR] [WOS]
  7. Bavli Yaelle, Chen Bing-Mae, Gross Guy, Hershko Alon, Turjeman Keren, Roffler Steve, Barenholz Yechezkel Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). Journal of Controlled Release 354, 316-322 (2023-02) [JCR] [WOS]
  8. Lin YC, Chen BM, Tran TTM, Chang TC, Al-Qaisi TS, Roffler SR* Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture.. Journal of controlled release : official journal of the Controlled Release Society 354, 354-367 (2023-01) [JCR] [WOS]
  9. Burnouf PA, (Roffler SR), Wu CC, Su YC Glucuronides: From biological waste to bio-nanomedical applications.. Journal of controlled release : official journal of the Controlled Release Society 349, 765-782 (2022-09) [JCR] [WOS]
  10. Sahoo BK, Lin YC, Tu CF, Lin CC, Liao WJ, Li FA, Li LH, Mou KY, (Roffler SR), Wang SP, Yeh CT, Yao CY, Hou HA, Chou WC, Tien HF, Yang RB* Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia.. Haematologica 10.3324/haematol.2022.281151, x (2022-08) [JCR] [WOS]
- More Publications-

- POSTDOC -
member
Tseng, Yi-Han
member
Chang, Shelly
member
Chiu, Po-Chuan
Burnouf, Pierre-Alain
Burnouf, Pierre-Alain
- RESEARCH ASSOCIATES -
member
Wu, Penny
member
Tang, Hsiyang
member
Lin, Sam
member
Chang, Deng-Yuan(Peter)
Yang, Seymour
Yang, Seymour
- STUDENTS -
Lin, Ronald
Lin, Ronald
- ALUMNI -
member
Prijovich, Sunny